EUVIMEDEUVIMED entdecken
Crossref

Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles

Alberto Foncillas iD, Juan Ambrosioni, Abiu Sempere, Leire Berrocal, Julia Calvo iD, Iván Chivite iD, Lorena de la Mora, Alexy Inciarte, Berta Torres, María Martínez-Rebollar iD, José Luis Blanco, José M Miró iD und 5 weitere

Clinical Infectious Diseases · 08.07.2026 · 82 (6) · 1015-1022

DOI: 10.1093/cid/ciag023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Infectious Diseases, online erschienen am 14.01.2026. Verfasst von Alberto Foncillas und 16 weiteren Autor:innen. Beteiligte Einrichtung: HIV Unit, Infectious Diseases Service, Hospital Clínic Barcelona-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spa…. Hauptthemen laut MEDLINE: Hepatitis B, HIV Infections, Anti-HIV Agents, Pyridones. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Long-acting cabotegravir/rilpivirine (LA-CAB/RPV) therapy for HIV, lacks activity against hepatitis B virus (HBV). We evaluate HBV serological profiles and risk of HBV reactivation (HBVr) or incident infection (HBVi) in people with HIV (PWH) switching to LA-CAB/RPV.

Methods

Prospective cohort study of PWH initiating LA-CAB/RPV at Hospital Clínic Barcelona between February/2023 and February/2025. HBV serology, vaccination status, and liver function tests (LFTs) were assessed at baseline. Follow-up LFTs were performed routinely (weeks 12, 28, and every 6 months), and HBV serology/DNA assessed if abnormal LFTs, acute hepatitis or clinical suspicion of reactivation. HBVr was defined as conversion from HBsAg negative to positive or detectable HBV DNA in anti-HBc-positive/HBsAg-negative individuals, or as HBV DNA ≥1 log increase or ≥100 IU/mL in chronic HBV (HBsAg-positive) participants. HBVi was defined as HBsAg seroconversion in HBV unexposed individuals.

Results

Among 741 participants-92% cis-gender male, median age 43 (IQR 35–52)-454 (61%) had vaccine-induced immunity and 25% had prior HBV exposure (anti-HBc-positive), with 3% showing isolated anti-HBc. Median follow-up was 54 weeks (IQR 28–77). No HBVr or HBVi were observed in people without chronic hepatitis at baseline. Four individuals (0.5%) with unnoticed chronic HBV infection (HBsAg-positive) started LA-CAB/RPV; two developed clinical HBVr and two remained stable after regimen switch, all four switched back to tenofovir-containing therapy. Transaminase elevations during follow-up occurred in 17% of the cohort, regardless of HBV serostatus.

Conclusions

LA-CAB/RPV appears safe in individuals with prior HBV exposure, including isolated anti-HBc. Comprehensive HBV screening, vaccination, and liver monitoring are essential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hepatitis BHIV InfectionsAnti-HIV AgentsPyridonesHumansFemaleMaleAdultProspective StudiesVirus ActivationHepatitis B virusMiddle AgedLiverLiver Function TestsAntiviral AgentsHepatitis B Surface AntigensHepatitis B AntibodiesBreakthrough InfectionsDNA, Viral

Stichwörter der Autor:innen

hepatitis B virus infectionhepatitis B virus reactivationlong-acting cabotegravir plus rilpivirinereal-world cohort

Substanzen

Anti-HIV AgentsPyridonesAntiviral AgentsHepatitis B Surface AntigensHepatitis B AntibodiesDNA, Viral

Autor:innen und Institutionen

  • HIV Unit, Infectious Diseases Service, Hospital Clínic Barcelona-Instituto de Investigaciones Biomédicas August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Faculty of Medicine, University of Barcelona, Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.
  • Reial Academia de Medicina de Catalunya (RAMC), Barcelona, Spain.

ORCID-Profile: Alberto Foncillas, Julia Calvo, Iván Chivite, María Martínez-Rebollar, José M Miró, Elisa de Lazzari, Esteban Martínez, Josep Mallolas, Ana González-Cordón, Montserrat Laguno

Zitieren

APA

Foncillas, A., Ambrosioni, J., Sempere, A., Berrocal, L., Calvo, J., Chivite, I., de la Mora, L., Inciarte, A., Torres, B., Martínez-Rebollar, M., Blanco, J. L., Miró, J. M., de Lazzari, E., Martínez, E., Mallolas, J., González-Cordón, A., & Laguno, M. (2026). Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles. Clinical Infectious Diseases, 82(6), 1015-1022. https://doi.org/10.1093/cid/ciag023

Vancouver

Foncillas A, Ambrosioni J, Sempere A, Berrocal L, Calvo J, Chivite I, et al. Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles. Clinical Infectious Diseases. 2026;82(6):1015-1022. doi:10.1093/cid/ciag023

BibTeX
@article{Foncillas2026,
  author = {Foncillas, Alberto and Ambrosioni, Juan and Sempere, Abiu and Berrocal, Leire and Calvo, Julia and Chivite, Iván and de la Mora, Lorena and Inciarte, Alexy and Torres, Berta and Martínez-Rebollar, María and Blanco, José Luis and Miró, José M and de Lazzari, Elisa and Martínez, Esteban and Mallolas, Josep and González-Cordón, Ana and Laguno, Montserrat},
  title = {Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles},
  journal = {Clinical Infectious Diseases},
  year = {2026},
  volume = {82},
  number = {6},
  pages = {1015--1022},
  doi = {10.1093/cid/ciag023}
}
Kostenlos starten →